Clinical Trials

246 enrolled

Multiple Myeloma

NCT05434689 2026-04-15

COMMANDER

80 enrolled

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Multiple Myeloma, Neoplasms

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT05590377 2026-01-30

iinnovate-3

Phase 1/2 Terminated

15 enrolled 12 charts

Multiple Myeloma

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence

NCT04824794 2025-12-22

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Phase 1/2 Terminated

130 enrolled

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT05392946 2025-10-29

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

49 enrolled

Multiple Myeloma

NCT07075510 2025-10-29

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

30 enrolled

Neoplasms, Plasma Cell

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

37 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07090954 2025-07-29

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

32 enrolled

Multiple Myeloma

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

19 enrolled

Multiple Myeloma, Recurrence

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

53 enrolled

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

LymphoidOther hematologic neoplasmPlasma cell

128 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT03537599 2025-05-21

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Phase 1/2 Terminated

4 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04922723 2025-04-18

PRIDE